What is Axsome Therapeutics's operating lease liabilities?

Axsome Therapeutics (AXSM) reported operating lease liabilities of -$608K in Q1 2026.

How has Axsome Therapeutics's operating lease liabilities changed year-over-year?

Axsome Therapeutics's operating lease liabilities decreased by 392.3% year-over-year, from $208K to -$608K.

Axsome Therapeutics AXSM Operating lease liabilities

Operating lease liabilities at other companies

BridgeBio PharmaBBIO

——

Arrowhead ResearchARWR

——

Other financials

Income statement

See full

Revenue$191.2M+57.4%

Gross profit$176.5M+58.0%

Operating income-$63.4M-11.2%

Net income-$64.5M-8.6%

EPS (diluted)-$1.26-3.3%

Balance sheet

See full

Cash & equivalents$305.1M+1.4%

Total debt$219.9M+4.1%

Total equity$54.6M+2.6%

Total assets$713.6M+19.6%

Cash flow

See full

Operating cash flow-$20.7M+52.3%

CapEx$121.0K-64.2%

Free cash flow-$20.8M+52.4%

Valuation

See full

Market cap$12.89B+52.0%

Enterprise value$12.81B+52.9%

P/S18.2×-1.4×

Profitability

See full

Gross margin92.6%+1.1pp

Operating margin-24.4%-9.3pp

Net margin-26.6%-9.8pp

FCF margin-10.2%-3.9pp

Returns & leverage

See full

Return on equity-349.4%+109pp

Debt / equity4×+0.1×

Current ratio1.4×-0.6×

Where this comes from

Reported directly by Axsome Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Axsome Therapeutics's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Axsome Therapeutics's operating lease liabilities?: Axsome Therapeutics (AXSM) reported operating lease liabilities of -$608K in Q1 2026.
How has Axsome Therapeutics's operating lease liabilities changed year-over-year?: Axsome Therapeutics's operating lease liabilities decreased by 392.3% year-over-year, from $208K to -$608K.